Parasym recently partnered with a research team at the Human Waves Clinic and Laboratory of Neurophysiology & Movement Biomechanics at Université Libre de Bruxelles in Belgium. The research study analyzed the impact of our targeted neuromodulation technology on the persisting symptoms of Long-COVID. The goal was to determine if Parasym’s targeted neuromodulation could be an effective treatment for Long-COVID symptoms.
The Silent Impact of Long-COVID
Long-COVID refers to ongoing symptoms that continue even after people have recovered from the acute symptoms of the Covid-19 virus. Long-COVID patients typically suffer from a combination of chronic fatigue, brain fog, pain/body aches, and shortness of breath.
At the date of writing over 1 million people have reported struggling with Long-COVID symptoms in the UK.
Due to the global scale of the Covid-19 pandemic, Long-COVID is expected to put a continued burden on healthcare systems, with the potential to contribute to long-lasting economic effects as well. As it stands, there are no currently established medications, or medical devices specifically targeted to resolve Long-COVID symptoms.
The lingering effects of Covid-19 appear to stem from a lasting imbalance in the nervous system as the virus can persist in neural tissue long after people recover from the initial infection. This is where neuromodulation shows great promise as an effective, safe solution.
What is Neuromodulation?
Neuromodulation works to re-establish the normal functioning of the nervous system through a process similar to how cardiac pacemakers correct abnormal heartbeats. By sending targeted signals to specific neural circuits in the body via the vagus nerve, it’s possible to correct irregular signals that can cause these crippling symptoms. This results in improved physical and mental function.
Neuromodulation has fascinated doctors for decades and has recently shown exceptional results in a number of clinical studies. It is now a clinically proven approach to relieve a host of different health conditions and symptoms including depression, fatigue, anxiety, and stress.
The Parasym device spent years in development alongside the world’s leading clinical research centers to provide a safe and effective neuromodulation treatment.
How Parasym Works
Parasym harnesses the power of advanced neuromodulation technology into a simple, safe, and effective handheld device anyone can use right from their home. It is the most accessible and affordable certified neuromodulation device on the market.
Parasym has demonstrated remarkable effectiveness in double-blind clinical trials and is now being utilized by trusted global leaders in the medical field including Harvard, UCL, and the Imperial College Healthcare NHS Trust.
The Parasym device works by modulating the vagus nerve through a pathway that runs past the outer ear. It is a non-invasive, low-risk device that doesn’t require any medical procedures or medication to function properly.
Parasym consists of two key parts: the main device which delivers the neuromodulation signals and a comfortable earpiece that targets these signals to the vagus nerve. The connected control pad allows users to easily control the level of the neuromodulation signals to meet their needs.
By restoring the balance and health of your nervous system, you can reignite your passion for life, uplift your mood, and regain the energy you need to get the most out of every day.
Results of Long-COVID Study
The study conducted at the Human Waves Clinic and Université Libre de Bruxelles showed great promise in both the treatment of Long-COVID and the efficacy of neuromodulation as a treatment for a range of different health conditions. The 20 patients enrolled in the study had been experiencing Long-COVID symptoms as long as 32 weeks after their acute infection from the virus (22 weeks on average). Their most common symptoms were fatigue, cognitive issues, pain, and difficulty breathing. The combination of symptoms experienced often led patients to a feeling of helplessness, thus leading to more depressive emotional states.
We were pleased to see that all 20 patients improved dramatically during the 14-day treatment period. By utilizing Parasym to modulate the vagus nerve, the study authors concluded that patients improved their Long-COVID symptoms thanks to a targeted autonomic reset. Remarkably, it only took 10 sessions with Parasym for patients to show a “very significant improvement” which remained even one week after ending treatment.
We hope that this study sparks a deeper inquiry into the benefits of neuromodulation as an effective treatment for Long-COVID and leads to wider adoption of neuromodulation to treat a range of different health issues.
Our work is on the frontier of developments in the field of Bioelectric Medicine.
Ask us anything: